Literature DB >> 17653645

The epidemiology of hepatitis C infection in the United States.

Vinod K Rustgi1.   

Abstract

BACKGROUND: The prevalence of hepatitis C virus (HCV) infection in the United States has remained constant from 1988 through 2002, although the peak age of infection has increased. While the number of new HCV cases is declining, the rates of HCV-associated morbidity and mortality are increasing. We reviewed the risk factors for HCV infection, the laboratory methods used to diagnose it, the dynamics of disease progression, and the natural history of HCV infection.
METHODS: Medline searches were performed using the key word HCV, together with incidence, risk factors, demographics, diagnostic methods, disease progression, natural history, normal alanine aminotransferase (ALT), fibrosis, and hepatocellular carcinoma (HCC).
RESULTS: Three characteristics-abnormal serum ALT, history of injection drug use, and blood transfusion before 1992-identified 85% of HCV-positive individuals 20-59 years old. About 75%-85% of acutely infected individuals progress to chronic infection, with up to 20% developing liver cirrhosis over 20-25 years, putting them at increased risk for end-stage liver disease and/or HCC. HCV-associated cirrhosis is the leading cause of liver transplantation in the United States. Rates of infection are higher in non-Hispanic blacks than in non-Hispanic whites and Mexican Americans and higher in men than in women. In the United States, over 70% of HCV-infected individuals are infected with genotype 1.
CONCLUSIONS: HCV infection is more prevalent than human immunodeficiency virus or hepatitis B virus infection and is particularly common among certain demographic groups. Individual rates of fibrosis progression vary, but identification of host and viral characteristics associated with disease progression may reveal the mechanisms of HCV-associated hepatic fibrosis/cirrhosis.

Entities:  

Mesh:

Year:  2007        PMID: 17653645     DOI: 10.1007/s00535-007-2064-6

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  71 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

2.  Mortality from hepatocellular and biliary cancers: changing epidemiological trends.

Authors:  Satheesh Nair; K Shiv Kumar; Paul J Thuluvath; K S Shivakumar; K Shiva Kumar
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

3.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.

Authors:  M Vogt; T Lang; G Frösner; C Klingler; A F Sendl; A Zeller; B Wiebecke; B Langer; H Meisner; J Hess
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

Review 4.  Developments in the treatment of chronic hepatitis C.

Authors:  Paul J Pockros
Journal:  Expert Opin Investig Drugs       Date:  2002-04       Impact factor: 6.206

5.  Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C.

Authors:  F Ramalho; A Costa; A Pires; P Cabrita; F Serejo; A P Correia; N Fatela; H Clória; J Lopes; H C Pinto; R Marinho; M Raimundo; J Velosa; A Batista; M C de Moura
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

6.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 7.  Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics.

Authors:  Jean-Michel Pawlotsky
Journal:  Semin Liver Dis       Date:  2003       Impact factor: 6.115

8.  Prevalence of Hepatitis C virus infection in a sample of homeless veterans.

Authors:  Rani A Desai; Robert A Rosenheck; Vincent Agnello
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2003-07       Impact factor: 4.328

Review 9.  Chronic hepatitis C in African Americans and other minority groups.

Authors:  Jaquelyn Fleckenstein
Journal:  Curr Gastroenterol Rep       Date:  2004-02

Review 10.  A rational use of laboratory tests in the diagnosis and management of hepatitis C virus infection.

Authors:  Gianna Dal Molin; Claudio Tiribelli; Cesare Campello
Journal:  Ann Hepatol       Date:  2003 Apr-Jun       Impact factor: 2.400

View more
  49 in total

1.  Hepatitis C among clients of health care for the homeless primary care clinics.

Authors:  Aaron J Strehlow; Marjorie J Robertson; Suzanne Zerger; Catherine Rongey; Lisa Arangua; Ed Farrell; Adele O'Sullivan; Lillian Gelberg
Journal:  J Health Care Poor Underserved       Date:  2012-05

2.  Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.

Authors:  Andreas Walker; Kathrin Skibbe; Eike Steinmann; Stephanie Pfaender; Thomas Kuntzen; Dominik A Megger; Svenja Groten; Barbara Sitek; Georg M Lauer; Arthur Y Kim; Thomas Pietschmann; Todd M Allen; Joerg Timm
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

3.  Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico.

Authors:  Lilliana Morales-Vásquez; Edgar I Miranda-Avalo; José R Rodríguez-Medina; Yomarid Quiñones-Badillo; Juan Marqués-Lespier; José Muñoz-Acabá; Rafael Pastrana; Cynthia M Pérez-Cardona; Yasuhiro Yamamura; Esther A Torres
Journal:  P R Health Sci J       Date:  2014-12       Impact factor: 0.705

4.  Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Authors:  Jagpreet Chhatwal; Shannon A Ferrante; Cliff Brass; Antoine C El Khoury; Margaret Burroughs; Bruce Bacon; Rafael Esteban-Mur; Elamin H Elbasha
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

5.  Association between hepatitis B virus and pancreatic cancer.

Authors:  Manal M Hassan; Donghui Li; Adel S El-Deeb; Robert A Wolff; Melissa L Bondy; Marta Davila; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

6.  Analysis of the 5'UTR of HCV genotype 3 grown in vitro in human B cells, T cells, and macrophages.

Authors:  Dennis Revie; Michael O Alberti; John G Prichard; Ann S Kelley; S Zaki Salahuddin
Journal:  Virol J       Date:  2010-07-13       Impact factor: 4.099

7.  Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection.

Authors:  Maarit Sillanpää; Krister Melén; Päivi Porkka; Riku Fagerlund; Kaisu Nevalainen; Maija Lappalainen; Ilkka Julkunen
Journal:  Virol J       Date:  2009-06-23       Impact factor: 4.099

8.  JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma.

Authors:  Qingshan Chang; Jianguo Chen; Kevin J Beezhold; Vince Castranova; Xianglin Shi; Fei Chen
Journal:  Mol Cancer       Date:  2009-08-17       Impact factor: 27.401

9.  Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States.

Authors:  Robert J Wong; Douglas A Corley
Journal:  Dig Dis Sci       Date:  2009-01-01       Impact factor: 3.199

10.  Hepatitis C seroprevalence and associated risk factors, Anyang, China.

Authors:  Fangfang Liu; Ke Chen; Zhonghu He; Tao Ning; Yaqi Pan; Hong Cai; Yang Ke
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.